A federal advisory panel has recommended opening a legal path to a class of trendy compounds that many people are already buying and injecting despite their not being approved, and the vote was closer, and more contested, than the headline suggests, LAist reports.
What was decided
An FDA advisory committee reviewed seven peptide therapies, none of them FDA-approved, and voted by narrow margins to recommend the agency reclassify almost all of them so that specialized compounding pharmacies could legally produce them. Six got a favorable recommendation; only one, a sleep-related compound called emideltide, was voted down.
The list is a tour of the wellness internet: BPC-157, promoted for gut conditions such as ulcerative colitis; TB-500; MOTS-c; KPV; the anti-aging compound epitalon, sometimes taken for sleep; and semax. At present these cannot legally be manufactured in the United States except for research, which is precisely how a gray market formed.
The gray market the vote is chasing
Because the compounds are effectively unavailable through legitimate channels, users have turned to unvetted products sold online under labels like "for research use only" and "not for human consumption," a wink-and-nod dodge that lets sellers ship substances people then inject. The strongest argument for the panel's recommendation is harm reduction: if people are going to use these anyway, better they get them from a regulated compounding pharmacy than from an anonymous vial of unknown contents.
"You will see many, many different forms," FDA official Russell Wesdyk said of the inconsistent chemistry in the current market. Telehealth entrepreneur Brigham Buhler, arguing for access, framed the goal as ensuring "safe and effective manufacturing," not enabling an uncontrolled market.
The doubts, including from inside the FDA
Against that, the agency's own scientists laid out a serious list of concerns: a lack of large, controlled human trials establishing safety or effectiveness, some compounds with no published human studies at all, and potential risks including encouraging cancer growth and provoking severe immune responses. That is the crux of the tension, a recommendation to widen access to things that have not been through the testing approval normally requires.
Some panelists balked. Dr. Elizabeth Rebello worried the panel was "responding to market-induced demand rather than a decision based in solid science," and Dr. Brian Lee said he could not "in good conscience vote yes." Adding to the scrutiny, eight new members had been appointed before the meeting, most with industry ties, though the Department of Health and Human Services said standard ethics vetting was done.
What happens next
A recommendation is not a rule. If the FDA accepts it, a formal rulemaking process could stretch into 2028, though Health Secretary Robert F. Kennedy Jr. could in theory use special authority to move faster. The panel is set to reconvene in February to weigh additional peptides.
For readers, the practical takeaway is caution rather than green light. The panel's vote reflects a real problem, an unregulated market people are already using, but it does not mean these peptides have been shown to be safe or to work. The Herald will report what the FDA does with the recommendation, and on what timeline.
